Vir Biotechnology president and CEO George Scangos explains why many companies struggle to build a sustainable business model around fighting infectious diseases, particularly when it comes to developing antibiotics. However, he adds, certain therapies for viral diseases are currently more financially viable. Dr. Scangos explores why Vir decided to go “all-in” on infectious diseases, how they built a company around that mission, and how the arrival of COVID-19 impacted the young company’s trajectory.
Related
Claire Hughes Johnson,
Stripe
Scaling Operations and People [Entire Talk]
Build a company that is ready to scale with a strong foundation of values, well-built operating structures, and a complementary team.
Claire Hughes Johnson,
Stripe
Scaling Operations and People [Entire Talk]
Build a company that is ready to scale with a strong foundation of values, well-built operating structures, and a complementary team.
Julia Collins,
Planet FWD
Opportunities in Climate Tech [Entire Talk]
To build a sustainable future, we need to focus on decarbonization - and the climate technology market is ripe with opportunity.
Julia Collins,
Planet FWD
Opportunities in Climate Tech [Entire Talk]
To build a sustainable future, we need to focus on decarbonization - and the climate technology market is ripe with opportunity.
Ben Collier,
The Farmlink Project
James Kanoff,
The Farmlink Project
Students Solving Hunger [Entire Talk]
As mission-driven nonprofits grow, they must stay anchored in their values and strengthen their community.
Ben Collier,
The Farmlink Project
James Kanoff,
The Farmlink Project
Students Solving Hunger [Entire Talk]
As mission-driven nonprofits grow, they must stay anchored in their values and strengthen their community.
